Next Generation Exome Sequencing of Pediatric Asthma Identifies Rare and Novel Variants in Candidate Genes

Table 1

Summary of selected patients phenotypes and characteristics.

ID	Diagnosis	Gender	Age at diagnosis (year)	Blood eosinophil (%)	PFT	Treatment
					FEV1 %; Predected
1	BA	M	5.1	0.2	89%	β-Agonists and steroids
2	BA	F	5.9	0.22	90%	β-Agonists and steroids
3	BA/obese	M	8	0.26	89%	β-Agonists and steroids
4	BA	M	6	0.18	92%	β-Agonists and steroids
5	BA	M	5.5	0.41	83%	β-Agonists and steroids
6	BA	M	6.5	0.29	87%	β-Agonists and steroids
7	BA	M	6	7.57%	NA	β-Agonists and antihistaminic
8	BA (uncontrolled)	M	7.5	10.6%	NA	β-Agonists and steroids
9	BA	M	5	0.32	87%	β-Agonists and steroids

Table legend: phenotypic data of the patients (in addition to clinical and physiological assessment data including pulmonary function test, blood eosinophil percent, and the treatment used. PFT not performed for both samples 7 and 8). Note 1: sample 9 was selected but removed after Qc of genomic data. Note 2: the ID column includes the code number of the sample between brackets. BA: bronchial asthma; PFT: pulmonary function test.